Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study

Steven Ford;William E. Tente;

Publication

Article

November 15, 2001

BioPharm International

BioPharm International-11-01-2001

Volume14

Issue 11

Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study

Author(s):

Steven Ford,William E. Tente

by Steven Ford and William E. Tente Chimeric Therapies, Inc. Experience shows that murine MAbs used in cell therapy manufacturing can be produced with safety concerns in mind. In such cases, adequate characterization ensures that they retain functional integrity.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Business Matters: Eclipsed by Catastrophe

Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography

Designs for Bioassays with Plate Location Effects

Liposomes (a Review), Part One: Manufacturing Issues

Simplifying Pharmacologic Analysis with Programmable Scientific Software

Outsourcing Outlook: Truth in Outsourcing

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!